Dr. Lotte Bjerre Knudsen, PhD

Novo Nordisk A/S における Chief Scientific Advisor & Head of GLP-1 CoE

スピーカー

Lotte Bjerre Knudsen is the Chief Scientific Advisor for the SCO of Novo Nordisk. She heads up the team IDEA (Innovation & Data Experimentation Advancement) that focuses entirely on human data driven insights to inform drug discovery. Lotte has held her current role since 2022, after spending 2021 in Oxford. She is a long-time employee of Novo Nordisk, since 1989. Lotte is a co-inventor of liraglutide and has led all biology research programs for liraglutide and semaglutide from diabetes to obesity, cardiovascular, liver, kidney and Alzheimer’s Disease. She has been part of representing Novo Nordisk in five FDA Advisory committees. Lotte holds a degree in biotechnology from the Technical University of Denmark, and a Doctoral Degree in Scientific Medicine from the University of Copenhagen, and she is an Adjunct Professor of Translational Medicine for Aarhus University. Lotte has an H-index of 64, is an inventor on numerous patents, and most prominently a recipient of the Paul Langerhans Award, the Science Mani Bhaumik Breakthrough of the Year Award, the Lasker-DeBakey Clinical Research Award and the Breakthrough Prize of Life Sciences.